Garlic Powder: Benefits for Metabolic Syndrome and Cardiovascular Health
Individuals with metabolic syndrome (MetS) are particularly at a higher risk of cardiovascular diseases (CVD). One contributing factor to MetS pathogenesis is an imbalanced intestinal microbiota.
Recent hypotheses suggest that garlic may provide benefits in improving intestinal transit time and reducing cardiovascular risks.
To delve deeper into this topic, a three-month randomized double-blind controlled study was conducted, involving subjects with MetS. Ninety participants were randomly assigned to either the treatment group, receiving 1,600 mg/day of garlic powder, or the control group receiving a placebo.
Random subject allocation was performed using a computer-generated random number table. During the follow-up period, all participants were instructed to follow common healthy dietary recommendations.
Primary outcomes considered in the study included intestinal transit time, lipid accumulation product (LAP), and various cardiometabolic indices such as cardiometabolic index (CMI), atherogenic index of plasma (AIP), Castelli risk index I (CRI-I), and Castelli risk index II (CRI-II).
Results revealed significant improvements in the garlic powder group compared to the placebo group. Specifically, there was an improvement in intestinal transit time, reduction in LAP, and decrease in cardiometabolic indices, including CMI, AIP, CRI-I, and CRI-II.
Based on these findings, it can be concluded that garlic powder supplementation can lead to significant improvements in intestinal transit time, lipid accumulation product (LAP), and cardiometabolic indices in individuals with metabolic syndrome.
These results suggest that garlic could be considered as a potential therapeutic or preventive intervention for individuals at risk of cardiovascular diseases associated with metabolic syndrome.
If your company is interested in developing and/or producing a product for a potential therapeutic or preventive intervention for individuals at risk of cardiovascular diseases associated with metabolic syndrome.
If your company wants to develop and/or make a product for possible therapeutic or preventive intervention in people at risk of cardiovascular disease related to metabolic syndrome
